MA38711A1 - Utilisation des ligands des récepteurs sigma pour prévenir et traiter la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (ic/bps). - Google Patents
Utilisation des ligands des récepteurs sigma pour prévenir et traiter la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (ic/bps).Info
- Publication number
- MA38711A1 MA38711A1 MA38711A MA38711A MA38711A1 MA 38711 A1 MA38711 A1 MA 38711A1 MA 38711 A MA38711 A MA 38711A MA 38711 A MA38711 A MA 38711A MA 38711 A1 MA38711 A1 MA 38711A1
- Authority
- MA
- Morocco
- Prior art keywords
- bps
- pain associated
- prevent
- interstitial cystitis
- receptor ligands
- Prior art date
Links
- 208000005615 Interstitial Cystitis Diseases 0.000 title abstract 4
- 239000003982 sigma receptor ligand Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention porte sur l'utilisation d'un ligand sigma, en particulier d'un ligand sigma de formule (i) pour prévenir et/ou traiter une douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (ic/bps).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382246.0A EP2818166A1 (fr) | 2013-06-26 | 2013-06-26 | Utilisation de ligands des récepteurs sigma pour la prévention et le traitement de la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (IC/BPS) |
PCT/EP2014/063360 WO2014207024A1 (fr) | 2013-06-26 | 2014-06-25 | Utilisation des ligands des récepteurs sigma pour prévenir et traiter la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (ic/bps). |
Publications (1)
Publication Number | Publication Date |
---|---|
MA38711A1 true MA38711A1 (fr) | 2017-12-29 |
Family
ID=48700506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38711A MA38711A1 (fr) | 2013-06-26 | 2014-06-25 | Utilisation des ligands des récepteurs sigma pour prévenir et traiter la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (ic/bps). |
Country Status (19)
Country | Link |
---|---|
US (1) | US20160151377A1 (fr) |
EP (2) | EP2818166A1 (fr) |
JP (1) | JP2016523276A (fr) |
KR (1) | KR20160023839A (fr) |
CN (1) | CN105377257A (fr) |
AR (1) | AR096709A1 (fr) |
AU (1) | AU2014301220A1 (fr) |
BR (1) | BR112015032343A8 (fr) |
CA (1) | CA2916568A1 (fr) |
HK (1) | HK1221656A1 (fr) |
IL (1) | IL243362A0 (fr) |
MA (1) | MA38711A1 (fr) |
MX (1) | MX2015017761A (fr) |
PH (1) | PH12015502815A1 (fr) |
RU (1) | RU2016102149A (fr) |
SG (1) | SG11201510408XA (fr) |
TN (1) | TN2015000558A1 (fr) |
TW (1) | TWI629984B (fr) |
WO (1) | WO2014207024A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116539A1 (fr) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance |
EP2353591A1 (fr) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance |
EP2353598A1 (fr) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire |
EP2388005A1 (fr) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie |
EP2415471A1 (fr) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes |
EP2524694A1 (fr) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Utilisation de ligands sigma dans la douleur liée au diabète de type 2 |
KR20160097366A (ko) | 2013-12-17 | 2016-08-17 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 세로토닌-노르에피네프린 재흡수 억제제들(SNRIs) 및 시그마 리셉터 리간드들 조합 |
WO2015091505A1 (fr) * | 2013-12-17 | 2015-06-25 | Laboratorios Del Dr. Esteve, S.A. | Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma |
CA3121202A1 (fr) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Composes pyrrole et pyrazole et leurs procedes d'utilisation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1270708C (zh) * | 2001-07-10 | 2006-08-23 | 安斯泰来制药有限公司 | 间质性膀胱炎治疗用医药组合物 |
BRPI0514692A (pt) | 2004-08-27 | 2008-06-17 | Esteve Labor Dr | inibidores do receptor sigma |
TWI356699B (en) * | 2004-11-10 | 2012-01-21 | Kissei Pharmaceutical | Agent for treating interstitial cystitis and agent |
WO2007025613A2 (fr) * | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de composes se liant au recepteur sigma pour traiter la douleur associee au diabete |
MX2008011016A (es) * | 2006-03-01 | 2008-09-08 | Esteve Labor Dr | Inhibidores de receptor sigma. |
CN101395157A (zh) * | 2006-03-01 | 2009-03-25 | 伊斯特芬博士实验室有限公司 | 作为西格玛受体抑制剂的吡唑衍生物 |
EP2113501A1 (fr) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazoles de 5-Methyl-1-(naphthalen-2-YL)-1H- utiles en tant qu'inhibiteurs de récepteur sigma |
EP2116539A1 (fr) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance |
EP2353591A1 (fr) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance |
EP2353598A1 (fr) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire |
EP2460804A1 (fr) * | 2010-12-03 | 2012-06-06 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de 5-méthyl-1-(naphthalen-2-yl)-1h-pyrazole et leur utilisation dans la potentialisation de l'effet des analgésiques opioïdes |
EP2460519A1 (fr) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Utilisation de ligands sigma pour la douleur du cancer des os |
RU2606131C2 (ru) * | 2011-05-13 | 2017-01-10 | Эррэй Биофарма Инк. | СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA |
EP2524694A1 (fr) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Utilisation de ligands sigma dans la douleur liée au diabète de type 2 |
-
2013
- 2013-06-26 EP EP13382246.0A patent/EP2818166A1/fr not_active Withdrawn
-
2014
- 2014-06-24 TW TW103121723A patent/TWI629984B/zh not_active IP Right Cessation
- 2014-06-24 AR ARP140102374A patent/AR096709A1/es unknown
- 2014-06-25 MX MX2015017761A patent/MX2015017761A/es unknown
- 2014-06-25 AU AU2014301220A patent/AU2014301220A1/en not_active Abandoned
- 2014-06-25 SG SG11201510408XA patent/SG11201510408XA/en unknown
- 2014-06-25 TN TN2015000558A patent/TN2015000558A1/en unknown
- 2014-06-25 CA CA2916568A patent/CA2916568A1/fr not_active Abandoned
- 2014-06-25 CN CN201480040098.1A patent/CN105377257A/zh active Pending
- 2014-06-25 JP JP2016522457A patent/JP2016523276A/ja active Pending
- 2014-06-25 EP EP14734099.6A patent/EP3013338A1/fr not_active Withdrawn
- 2014-06-25 WO PCT/EP2014/063360 patent/WO2014207024A1/fr active Application Filing
- 2014-06-25 KR KR1020167001865A patent/KR20160023839A/ko not_active Application Discontinuation
- 2014-06-25 MA MA38711A patent/MA38711A1/fr unknown
- 2014-06-25 RU RU2016102149A patent/RU2016102149A/ru not_active Application Discontinuation
- 2014-06-25 BR BR112015032343A patent/BR112015032343A8/pt not_active Application Discontinuation
- 2014-06-25 US US14/900,786 patent/US20160151377A1/en not_active Abandoned
-
2015
- 2015-12-17 PH PH12015502815A patent/PH12015502815A1/en unknown
- 2015-12-27 IL IL243362A patent/IL243362A0/en unknown
-
2016
- 2016-08-17 HK HK16109869.1A patent/HK1221656A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TWI629984B (zh) | 2018-07-21 |
US20160151377A1 (en) | 2016-06-02 |
SG11201510408XA (en) | 2016-01-28 |
BR112015032343A8 (pt) | 2018-01-23 |
IL243362A0 (en) | 2016-02-29 |
EP3013338A1 (fr) | 2016-05-04 |
TN2015000558A1 (en) | 2017-04-06 |
PH12015502815A1 (en) | 2016-03-21 |
KR20160023839A (ko) | 2016-03-03 |
RU2016102149A3 (fr) | 2018-05-25 |
HK1221656A1 (zh) | 2017-06-09 |
WO2014207024A1 (fr) | 2014-12-31 |
BR112015032343A2 (pt) | 2017-09-26 |
EP2818166A1 (fr) | 2014-12-31 |
JP2016523276A (ja) | 2016-08-08 |
AR096709A1 (es) | 2016-01-27 |
CN105377257A (zh) | 2016-03-02 |
MX2015017761A (es) | 2016-07-06 |
RU2016102149A (ru) | 2017-08-02 |
TW201536295A (zh) | 2015-10-01 |
AU2014301220A1 (en) | 2016-02-18 |
CA2916568A1 (fr) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38711A1 (fr) | Utilisation des ligands des récepteurs sigma pour prévenir et traiter la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (ic/bps). | |
MA35401B1 (fr) | Utilisation de ligands sigma dans une douleur associée au diabète de type 2 | |
MA42366A (fr) | Dispositif pour traiter, prévenir ou réduire la myopie, ou le risque de celle-ci | |
ZA201701299B (en) | Glycosidase inhibitors | |
MA38814B2 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
EA201691683A1 (ru) | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме | |
FR3004920B1 (fr) | Dispositif d'osteotomie, en particulier pour la realisation du scarf extreme dans le traitement de l'hallux valgus severe. | |
EA201691619A1 (ru) | Конденсированные гетероциклические соединения | |
MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
FR2975600B1 (fr) | Agents pour le traitement de tumeurs | |
BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
AR096893A1 (es) | Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro | |
EA201071248A1 (ru) | Дизамещенные фталазиновые антагонисты пути hedgehog | |
MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
MX2015014713A (es) | Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cancer. | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
MA41689A (fr) | Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine | |
PH12016502244A1 (en) | Hsp70 modulators and methods for making and using the same | |
MA34952B1 (fr) | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme | |
TR201900665T4 (tr) | Diyabetik nefropatinin tedavi yöntemi. | |
MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
FR3045392B1 (fr) | Dispositif pour le traitement d'un sujet par combinaison notamment de la lithotherapie, la chromotherapie, la luminotherapie et la musicotherapie | |
EA201790973A1 (ru) | A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона |